HLS Therapeutics (TSE:HLS) Hits New 12-Month Low – What’s Next?

HLS Therapeutics Inc. (TSE:HLS) reached a new 52-week low during trading on Thursday . The stock traded as low as C$4.11 and last traded at C$4.00, with a volume of 4274 shares trading hands. The stock had previously closed at C$4.12.

HLS Therapeutics Trading Down 1.9%

The stock has a market cap of C$126.35 million, a price-to-earnings ratio of -12.62 and a beta of -0.18. The business has a 50-day simple moving average of C$4.29 and a two-hundred day simple moving average of C$4.45. The company has a debt-to-equity ratio of 75.00, a quick ratio of 1.01 and a current ratio of 1.00.

HLS Therapeutics (TSE:HLS) last posted its quarterly earnings data on Friday, May 15th. The company reported C($0.10) earnings per share (EPS) for the quarter. HLS Therapeutics had a negative net margin of 18.42% and a negative return on equity of 16.54%. The business had revenue of C$17.88 million during the quarter. As a group, research analysts forecast that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.